- Home
- CSGP vs ROIV Comparison
CSGP vs ROIV Comparison
Compare CSGP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSGP | ROIV |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 20.7B |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CSGP | ROIV |
|---|---|---|
| Price | $33.58 | $27.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $67.00 | $28.94 |
| AVG Volume (30 Days) | ★ 5.3M | 4.5M |
| Earning Date | 04-28-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $965,230,000.00 | $29,053,000.00 |
| Revenue This Year | $19.71 | N/A |
| Revenue Next Year | $12.40 | $744.61 |
| P/E Ratio | $1,799.00 | ★ N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $34.75 | $10.58 |
| 52 Week High | $97.43 | $30.33 |
Technical Indicators
Market Signals| Indicator | CSGP | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 26.06 | 44.20 |
| Support Level | N/A | $26.94 |
| Resistance Level | $41.03 | $27.94 |
| Average True Range (ATR) | 1.73 | 0.87 |
| MACD | -0.14 | -0.20 |
| Stochastic Oscillator | 5.77 | 16.35 |
Price Performance
Historical ComparisonAbout CSGP CoStar Group Inc.
CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors spanning office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many well-respected brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence into Canada, the United Kingdom, Spain, and France.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.